IN2012DN00763A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00763A
IN2012DN00763A IN763DEN2012A IN2012DN00763A IN 2012DN00763 A IN2012DN00763 A IN 2012DN00763A IN 763DEN2012 A IN763DEN2012 A IN 763DEN2012A IN 2012DN00763 A IN2012DN00763 A IN 2012DN00763A
Authority
IN
India
Prior art keywords
diseases
hdl
prophylaxis
atherosclerosis
medicaments
Prior art date
Application number
Other languages
English (en)
Inventor
Stephan Roever
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN00763A publication Critical patent/IN2012DN00763A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN763DEN2012 2009-09-11 2010-09-08 IN2012DN00763A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170097 2009-09-11
PCT/EP2010/063136 WO2011029827A1 (fr) 2009-09-11 2010-09-08 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl

Publications (1)

Publication Number Publication Date
IN2012DN00763A true IN2012DN00763A (fr) 2015-06-26

Family

ID=42830122

Family Applications (1)

Application Number Title Priority Date Filing Date
IN763DEN2012 IN2012DN00763A (fr) 2009-09-11 2010-09-08

Country Status (34)

Country Link
US (1) US8227491B2 (fr)
EP (1) EP2475645B1 (fr)
JP (1) JP5604520B2 (fr)
KR (1) KR101382871B1 (fr)
CN (1) CN102639506B (fr)
AR (2) AR078352A1 (fr)
AU (1) AU2010294277B2 (fr)
BR (1) BR112012005511B8 (fr)
CA (1) CA2771493C (fr)
CL (1) CL2012000611A1 (fr)
CO (1) CO6491033A2 (fr)
CR (1) CR20120089A (fr)
CY (1) CY1114377T1 (fr)
DK (1) DK2475645T3 (fr)
EC (1) ECSP12011723A (fr)
ES (1) ES2423821T3 (fr)
HR (1) HRP20130869T1 (fr)
IL (1) IL217920A (fr)
IN (1) IN2012DN00763A (fr)
MA (1) MA33563B1 (fr)
MX (1) MX2012002254A (fr)
MY (1) MY161103A (fr)
NZ (1) NZ597514A (fr)
PE (1) PE20120863A1 (fr)
PL (1) PL2475645T3 (fr)
PT (1) PT2475645E (fr)
RS (1) RS52987B (fr)
RU (1) RU2541475C2 (fr)
SG (1) SG179035A1 (fr)
SI (1) SI2475645T1 (fr)
TW (1) TWI412363B (fr)
UA (1) UA107088C2 (fr)
WO (1) WO2011029827A1 (fr)
ZA (1) ZA201201599B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012031817A1 (fr) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Détermination des niveaux de protéine abca1 dans des cellules
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US20120101282A1 (en) * 2010-10-22 2012-04-26 Pascal Dott Process for the preparation of nicotinamide derivatives
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
WO2014180741A1 (fr) * 2013-05-06 2014-11-13 F. Hoffmann-La Roche Ag Procédés d'identification de modulateurs d'osbpl7 et utilisation de ces modulateurs pour traiter les maladies associées à osbpl7
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
US11814354B2 (en) 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
DK1868999T3 (da) * 2005-04-06 2009-08-17 Hoffmann La Roche Pyridin-3-carboxamidderivater som omvendte CB1-agonister
BRPI0717845A2 (pt) 2006-10-04 2015-06-16 Hoffmann La Roche Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos

Also Published As

Publication number Publication date
EP2475645A1 (fr) 2012-07-18
HK1172021A1 (en) 2013-04-12
AU2010294277A1 (en) 2012-02-09
ES2423821T3 (es) 2013-09-24
JP5604520B2 (ja) 2014-10-08
PE20120863A1 (es) 2012-07-23
CY1114377T1 (el) 2016-08-31
CN102639506A (zh) 2012-08-15
US8227491B2 (en) 2012-07-24
TWI412363B (zh) 2013-10-21
IL217920A0 (en) 2012-03-29
RU2541475C2 (ru) 2015-02-20
CN102639506B (zh) 2014-09-03
PT2475645E (pt) 2013-08-05
CL2012000611A1 (es) 2012-09-07
MY161103A (en) 2017-04-14
KR101382871B1 (ko) 2014-04-08
CR20120089A (es) 2012-03-22
ECSP12011723A (es) 2012-04-30
CA2771493C (fr) 2017-08-29
AR078352A1 (es) 2011-11-02
BR112012005511B1 (pt) 2021-03-02
BR112012005511B8 (pt) 2021-05-25
MX2012002254A (es) 2012-03-16
WO2011029827A1 (fr) 2011-03-17
CA2771493A1 (fr) 2011-03-17
RS52987B (sr) 2014-02-28
ZA201201599B (en) 2012-11-28
AR114032A2 (es) 2020-07-15
RU2012113924A (ru) 2013-10-20
BR112012005511A2 (pt) 2016-04-19
SG179035A1 (en) 2012-04-27
CO6491033A2 (es) 2012-07-31
US20110065759A1 (en) 2011-03-17
UA107088C2 (xx) 2014-11-25
HRP20130869T1 (hr) 2013-10-25
PL2475645T3 (pl) 2013-12-31
IL217920A (en) 2015-11-30
NZ597514A (en) 2013-10-25
JP2013504534A (ja) 2013-02-07
KR20120048040A (ko) 2012-05-14
EP2475645B1 (fr) 2013-07-03
SI2475645T1 (sl) 2013-10-30
DK2475645T3 (da) 2013-07-22
TW201114427A (en) 2011-05-01
AU2010294277B2 (en) 2015-07-09
MA33563B1 (fr) 2012-09-01

Similar Documents

Publication Publication Date Title
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
MX2013002660A (es) Heteroarilmetilamidas.
PH12019502355A1 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
IN2012DN01233A (fr)
IN2015DN01156A (fr)
MD20140002A2 (ro) Indazoli
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
TN2012000428A1 (en) Bisaryl-bonded aryltriazolones and use thereof
IN2014DN09434A (fr)
TN2011000414A1 (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
IN2012DN02081A (fr)
IN2012DN00971A (fr)
PH12014501319A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
MX2015008187A (es) Inhibidores de alk deuterados.
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
GB2511685A (en) Muscarinic m1 receptor agonists
MY157429A (en) Trpm8 antagonists and their use in treatments
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
IN2012DN00763A (fr)
MX342947B (es) Tratamiento de diabetes tipo 2.